Survival FU of JO25567 study

Survival folollow up of JO25567, a randomized phase 2 study comparing erlotinib and bevacizumab combination with erlotinib alone in NSCLC patients harboing EGFR mutaion

Status

Unknown

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080222518

Enrollment

121

Registered

2014-06-04

Start date

2014-06-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

investigational material(s) Generic name etc : erlotinib INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) The patient who had enrolled to JO25567 study and at least once received study medication without the patient who died and are lost to follow-up. (2)Signed informed consent after sufficient cralification for study contents

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
Overall survival This is defined as the time from the date of randomization for JO25567 study to the date of death, regardless of the cause of death. Patients with an unknown survival status at study end will be censored when they were last known to be alive.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026